{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:17:10Z","timestamp":1788599830352,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.yebeh.2022.108961","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T19:50:41Z","timestamp":1667245841000},"page":"108961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"PA","title":["Effectiveness and tolerability of adjunctive perampanel in the treatment of pediatric patients with uncontrolled epilepsy: A retrospective, single-center, real-world study"],"prefix":"10.1016","volume":"137","author":[{"given":"Li","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108961_b0005","doi-asserted-by":"crossref","unstructured":"Omran A, Elimam D, Yin F. MicroRNAs: new insights into chronic childhood diseases. Biomed Res Int. 2013;2013:291826. https:\/\/doi.org\/10.1155\/2013\/291826.","DOI":"10.1155\/2013\/291826"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108961_b0010","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40272-018-0302-4","article-title":"Pharmacokinetics and drug interaction of antiepileptic drugs in children and adolescents","volume":"20","author":"Iapadre","year":"2018","journal-title":"Paediatr Drugs"},{"issue":"2","key":"10.1016\/j.yebeh.2022.108961_b0015","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/14656566.2010.517194","article-title":"Pharmacotherapy for children and adolescents with epilepsy","volume":"12","author":"Verrotti","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.yebeh.2022.108961_b0020","doi-asserted-by":"crossref","unstructured":"Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies [published correction appears in Epilepsia. 2010;51(9):1922]. Epilepsia. 2010;51(6):1069-1077. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02397.x.","DOI":"10.1111\/j.1528-1167.2009.02397.x"},{"issue":"5","key":"10.1016\/j.yebeh.2022.108961_b0025","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/epi.13723","article-title":"The impact of seizures on epilepsy outcomes: A national, community-based survey","volume":"58","author":"Josephson","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2022.108961_b0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/epi.13604","article-title":"The burden of premature mortality of epilepsy in high-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy","volume":"58","author":"Thurman","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108961_b0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.yebeh.2018.01.039","article-title":"Antiepileptic drug treatment of generalized tonic-clonic seizures: An evaluation of regulatory data and five criteria for drug selection","volume":"82","author":"Shorvon","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108961_b0040","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2022.108961_b0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108961_b0050","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108961_b0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/ane.12879","article-title":"Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings","volume":"137","author":"Tsai","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"Suppl 1","key":"10.1016\/j.yebeh.2022.108961_b0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/epi.14456","article-title":"Perampanel: Does it have broad-spectrum potential?","volume":"60","author":"Potschka","year":"2019","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108961_b0065","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40263-021-00831-y","article-title":"Exploring the evidence for broad-spectrum effectiveness of perampanel: A systematic review of clinical data in generalised seizures","volume":"35","author":"Trinka","year":"2021","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.yebeh.2022.108961_b0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5698\/1535-7597.18.4.269","volume":"18","author":"Kanner","year":"2018","journal-title":"Epilepsy Curr"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108961_b0075","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/epi.13417","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety","volume":"57","author":"Lagae","year":"2016","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108961_b0080","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3345\/kjp.2018.06863","article-title":"Efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy","volume":"62","author":"Yun","year":"2019","journal-title":"Korean J Pediatr"},{"key":"10.1016\/j.yebeh.2022.108961_b0085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.seizure.2019.12.024","article-title":"The efficacy of perampanel in young children with drug-resistant epilepsy","volume":"75","author":"Chang","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108961_b0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"Suppl 3","key":"10.1016\/j.yebeh.2022.108961_b0095","first-page":"S17","article-title":"SCN1A-related phenotypes: Epilepsy and beyond","volume":"60","author":"Scheffer","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108961_b0100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.seizure.2019.05.024","article-title":"Successful treatment of intractable life-threatening seizures with perampanel in the first case of early myoclonic encephalopathy with a novel de novo SCN1A mutation","volume":"71","author":"Ishikawa","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108961_b0105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2017.05.036","article-title":"Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome","volume":"74","author":"Auvin","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108961_b0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2019.12.012","article-title":"Open-label, uncontrolled retrospective study of perampanel in adults with Lennox-Gastaut syndrome","volume":"75","author":"Crespel","year":"2020","journal-title":"Seizure"},{"issue":"10216","key":"10.1016\/j.yebeh.2022.108961_b0115","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108961_b0120","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: A randomized clinical trial","volume":"79","author":"Knupp","year":"2022","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108961_b0125","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00045415-199911000-00014","article-title":"Appetite-suppressing drugs and valvular heart disease","volume":"7","author":"Cannistra","year":"1999","journal-title":"Cardiol Rev"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108961_b0130","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/15563650.2018.1447119","article-title":"Drug-associated pulmonary arterial hypertension","volume":"56","author":"McGee","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108961_b0135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-020-00708-6","article-title":"Adjunctive cannabidiol in patients with Dravet syndrome: A systematic review and meta-analysis of efficacy and safety","volume":"34","author":"Lattanzi","year":"2020","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.yebeh.2022.108961_b0140","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40263-018-0558-9","article-title":"Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: A systematic review and meta-analysis","volume":"32","author":"Lattanzi","year":"2018","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108961_b0145","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","article-title":"Highly purified cannabidiol for epilepsy treatment: A systematic review of epileptic conditions beyond Dravet syndrome and Lennox-Gastaut syndrome","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108961_b0150","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/epi4.12623","article-title":"Effect of fenfluramine on seizures and comorbidities in SCN8A-developmental and epileptic encephalopathy: A case series","volume":"7","author":"Aledo-Serrano","year":"2022","journal-title":"Epilepsia Open"},{"issue":"9","key":"10.1016\/j.yebeh.2022.108961_b0155","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/epi.14522","article-title":"Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study","volume":"59","author":"Villanueva","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108961_b0160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.seizure.2020.09.026","article-title":"Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs","volume":"83","author":"Santamarina","year":"2020","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.yebeh.2022.108961_b0165","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1684\/epd.2021.1342","article-title":"Effectiveness and safety of perampanel in Chinese paediatric patients (2\u201314 years) with refractory epilepsy: a retrospective, observational study","volume":"23","author":"Qu","year":"2021","journal-title":"Epileptic Disord"},{"issue":"3","key":"10.1016\/j.yebeh.2022.108961_b0170","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cns.13458","article-title":"Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies","volume":"27","author":"Weiping","year":"2021","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"10.1016\/j.yebeh.2022.108961_b0175","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40266-021-00865-3","article-title":"Adjunctive perampanel in older patients with epilepsy: A multicenter study of clinical practice","volume":"38","author":"Lattanzi","year":"2021","journal-title":"Drugs Aging"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022004103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:47:23Z","timestamp":1761504443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022004103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":35,"alternative-id":["S1525505022004103"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108961","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and tolerability of adjunctive perampanel in the treatment of pediatric patients with uncontrolled epilepsy: A retrospective, single-center, real-world study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108961"}}